Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertugliflozin

FDA-approved product (tablet, oral), marketed as Ertugliflozin, Steglatro.

Registered studies
49
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ertugliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Ertugliflozin. Its therapeutic class is shown instead.

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ertugliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertugliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

    NCT02411929 · start 2014-10-29

    Registered record
    Registry ID
    NCT02411929
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Unlabeled ertugliflozin for oral use; 14^C-labeled ertugliflozin for IV use; 14^C-labeled ertugliflozin for oral use
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10-29
    Completion
    2015-02-09
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionUnlabeled ertugliflozin for oral use; 14^C-labeled ertugliflozin for IV use; 14^C-labeled ertugliflozin for oral use
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

    NCT02226003 · start 2014-09-23

    Registered record
    Registry ID
    NCT02226003
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin; Sitagliptin; Placebo to Ertugliflozin; Placebo to Sitagliptin; Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-09-23
    Completion
    2016-02-23
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin; Sitagliptin; Placebo to Ertugliflozin; Placebo to Sitagliptin +1 more
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

    NCT02115347 · start 2014-09-19

    Registered record
    Registry ID
    NCT02115347
    Conditions
    Type 2 Diabetes Mellitus; Hepatic Impairment
    Interventions
    Ertugliflozin 15 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09-19
    Completion
    2015-01-19
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Hepatic Impairment
    InterventionErtugliflozin 15 mg
    PhasePhase 1
    Registry statusCompleted

  • Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

    NCT02099110 · start 2014-04-22

    Registered record
    Registry ID
    NCT02099110
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Matching Placebo to Ertugliflozin 5 mg; Matching Placebo to Ertugliflozin 10 mg; Matching Placebo to sitagliptin 100 mg; Ertugliflozin 5 mg; Ertugliflozin 10 mg; Sitagliptin 100 mg; Metformin >= 1500 mg/day; Insulin Glargine Rescue Medication; Glimepiride Rescue Medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-04-22
    Completion
    2016-05-26
    Enrolment
    1,233

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionMatching Placebo to Ertugliflozin 5 mg; Matching Placebo to Ertugliflozin 10 mg; Matching Placebo to sitagliptin 100 mg; Ertugliflozin 5 mg +5 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

    NCT02036515 · start 2014-03-12

    Registered record
    Registry ID
    NCT02036515
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo for ertugliflozin 5 mg; Metformin; Sitagliptin; Glimepiride; Insulin; Placebo for ertugliflozin 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03-12
    Completion
    2016-06-06
    Enrolment
    464

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin 5 mg; Ertugliflozin 15 mg; Placebo for ertugliflozin 5 mg; Metformin +4 more
    PhasePhase 3
    Registry statusCompleted

  • Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

    NCT01999218 · start 2013-12-16

    Registered record
    Registry ID
    NCT01999218
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin 5 mg; Ertugliflozin 10 mg; Glimerpiride; Placebo to Ertugliflozin; Placebo to Glimepiride; Metformin; Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-16
    Completion
    2017-04-18
    Enrolment
    1,326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin 5 mg; Ertugliflozin 10 mg; Glimerpiride; Placebo to Ertugliflozin +3 more
    PhasePhase 3
    Registry statusCompleted

  • A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

    NCT02033889 · start 2013-12-13

    Registered record
    Registry ID
    NCT02033889
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride; Placebo to Glimepiride; Basal Insulin; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-13
    Completion
    2017-08-03
    Enrolment
    621

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to Ertugliflozin; Glimepiride +3 more
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

    NCT01986855 · start 2013-12-02

    Registered record
    Registry ID
    NCT01986855
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin 5 mg; Placebo 5 mg; Ertugliflozin 10 mg; Placebo 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-02
    Completion
    2016-09-28
    Enrolment
    468

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin 5 mg; Placebo 5 mg; Ertugliflozin 10 mg; Placebo 10 mg
    PhasePhase 3
    Registry statusCompleted

  • Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

    NCT01986881 · start 2013-11-04

    Registered record
    Registry ID
    NCT01986881
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin; Placebo; Glycemic Rescue
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-11-04
    Completion
    2019-12-27
    Enrolment
    8,246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin; Placebo; Glycemic Rescue
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

    NCT01958671 · start 2013-10-09

    Registered record
    Registry ID
    NCT01958671
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin 5 mg; Ertugliflozin 10 mg; Placebo to Ertugliflozin; Metformin; Placebo to Metformin; Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-10-09
    Completion
    2016-07-28
    Enrolment
    461

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin 5 mg; Ertugliflozin 10 mg; Placebo to Ertugliflozin; Metformin +2 more
    PhasePhase 3
    Registry statusCompleted

  • Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

    NCT01948986 · start 2013-10-01

    Registered record
    Registry ID
    NCT01948986
    Conditions
    Renal Impairment; Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10-01
    Completion
    2014-10-16
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment; Type 2 Diabetes Mellitus
    InterventionErtugliflozin
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)

    NCT01223339 · start 2010-10

    Registered record
    Registry ID
    NCT01223339
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Ertugliflozin; Placebo; Ertugliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionErtugliflozin; Placebo; Ertugliflozin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

    NCT01127308 · start 2010-06

    Registered record
    Registry ID
    NCT01127308
    Conditions
    Type 2 Diabetes Mellitus (T2DM)
    Interventions
    Ertugliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-06
    Completion
    2010-07
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus (T2DM)
    InterventionErtugliflozin
    PhasePhase 1
    Registry statusCompleted

  • Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

    NCT01096667 · start 2010-05-17

    Registered record
    Registry ID
    NCT01096667
    Conditions
    Diabetes Mellitus, Type 2; Hypertension
    Interventions
    Placebo to Ertuglilflozin 1 or 5 mg; Ertugliflozin 1 mg; Ertugliflozin 5 mg; Ertugliflozin 25 mg; HCTZ 12.5mg; Placebo to HCTZ; Placebo to ertuglilflozin 25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05-17
    Completion
    2011-02-25
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Hypertension
    InterventionPlacebo to Ertuglilflozin 1 or 5 mg; Ertugliflozin 1 mg; Ertugliflozin 5 mg; Ertugliflozin 25 mg +3 more
    PhasePhase 2
    Registry statusCompleted

  • Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

    NCT01114568 · start 2010-05

    Registered record
    Registry ID
    NCT01114568
    Conditions
    Healthy
    Interventions
    Ertugliflozin 10 mg tablet; Ertugliflozin OC Fast; Ertugliflozin OC Slow
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-05
    Completion
    2010-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionErtugliflozin 10 mg tablet; Ertugliflozin OC Fast; Ertugliflozin OC Slow
    PhasePhase 1
    Registry statusCompleted